

1 **Brief Communication:**

2 **The role of M1 to M2 macrophage polarization in the etiology of idiopathic gastroparesis:**  
3 **GWAS perspective**

4 Sandra P. Smieszek Ph.D., Jesse L. Carlin Ph.D., Changfu Xiao, Christos M. Polymeropoulos,  
5 Gunther Birznieks, Mihael H. Polymeropoulos, MD

6 <sup>1</sup>Vanda Pharmaceuticals Inc., 2200 Pennsylvania NW, Suite 300-E, Washington, DC 20037

7 **corresponding author: [sandra.smieszek@vandapharma.com](mailto:sandra.smieszek@vandapharma.com)**

8

9 **Abstract**

10

11 Gastroparesis is a serious medical condition characterized by delayed gastric emptying and  
12 symptoms of nausea, vomiting, bloating, fullness after meals, and abdominal pain. An innate  
13 immune dysregulation and injury to the interstitial cells of Cajal and other components of the  
14 enteric nervous system are likely central to the pathogenesis of gastroparesis. Thus far, little is  
15 known about the underlying genetic risk factors for gastroparesis. To ascertain these genetic risk  
16 factors for gastroparesis we conducted the first large whole-genome sequencing genome-wide  
17 association study (GWAS) analysis of gastroparesis patients.

18 The GWAS focused on idiopathic and diabetic gastroparesis cases as compared to matched  
19 controls as well as compared idiopathic versus diabetic cases. Amongst the top variants, we  
20 report a novel genetic risk variant for idiopathic gastroparesis - genetic association of the *Solute*  
21 *Carrier Family 15 (SLC15)* locus. This signal is driven by multiple variants with top missense  
22 variant SLC15A4:NM145648:exon2:c.T716C:p.V239A, rs33990080. SLC15A4 was shown to  
23 mediate M1-prone metabolic shifts in macrophages and guards immune cells from metabolic  
24 stress. The risk variant carriers have a significantly higher nausea score at baseline. We also  
25 delineated a number of statistically significant loci including novel ones as well as previously  
26 known loci such as *HLA-DQB1* - rs9273363, variant associated with Type 1 diabetes..

27 The GWAS picture that is emerging implicates the role of the machinery of M1 to M2  
28 macrophage polarization in the etiology of idiopathic gastroparesis. We suggest that macrophage  
29 polarization fate could lead to the destruction of the interstitial cells of Cajal which effectively  
30 leads to abnormal gastric emptying.

31

32

33

## 34 Introduction

35

36 Gastroparesis is a serious medical condition characterized by delayed gastric emptying in the  
37 absence of mechanical obstruction<sup>1</sup>. The main symptoms include nausea, vomiting, bloating,  
38 fullness after meals, and abdominal pain<sup>1</sup>. The overall standardized prevalence of gastroparesis is  
39 267.7 per 100,000 US adults, whereas the prevalence of “definite” gastroparesis is 21.5 per  
40 100,000<sup>2</sup>. Common etiologies include diabetes, post-surgical gastroparesis and idiopathic  
41 gastroparesis (with estimates of idiopathic (~11.3%) vs diabetic (>51.7%))<sup>2</sup>.

42 An innate immune dysregulation and injury to the interstitial cells of Cajal (ICC) and other  
43 components of the enteric nervous system through paracrine and oxidative stress mediators are  
44 likely central to the pathogenesis of gastroparesis<sup>3</sup>. Loss of antral CD206 positive anti-  
45 inflammatory macrophages is a key feature in human gastroparesis and it associates with ICC  
46 loss<sup>4</sup>. A review of the literature suggests that oxidative stress associated with diabetes activates  
47 macrophages. Activation of CD206 +, anti-inflammatory M2 macrophages expressing heme  
48 oxygenase 1 (HO1) is protective while activation of pro-inflammatory M1 macrophages which  
49 lack HO1 is injurious and leads to the development of delay in gastric emptying<sup>5</sup>. Low numbers  
50 of M2 macrophages were correlated with loss of ICC and were associated with both idiopathic  
51 and diabetic gastroparesis<sup>4</sup>. Importantly, when the anti-inflammatory M2 macrophages were  
52 switched to pro-inflammatory M1 macrophages, delayed GE was evident in animal models<sup>4</sup>.

53 Consistent with this notion is gastroparesis in patients receiving immune checkpoint inhibitors –  
54 blockage to PD-1/PD1-L and the resultant damage to the anti-inflammatory macrophages<sup>6</sup>. It is  
55 plausible that the blockage of PD-1/PD-L1 by ICI contributes to the onset of gastroparesis as a  
56 result of an immune-related adverse event. This is consistent with the decreased production of  
57 protective cytokines by M2 macrophages which was shown in acute lung injury with the  
58 blockage of PD-1/PD1-L<sup>6</sup>.

59

60 Thus far, there little is known regarding the common genetic risk factors for idiopathic  
61 gastroparesis. Prior studies reported Longer poly-GT repeats in the HMOX1 gene are more  
62 common in African Americans with gastroparesis, particularly in patients with diabetes<sup>7</sup>. To  
63 ascertain the genetic risk factors for gastroparesis we conducted a large whole-genome  
64 sequencing (WGS) of samples obtained from well clinically characterized gastroparesis studies  
65 of both diabetic and idiopathic gastroparesis. We have done a GWAS comparing idiopathic and  
66 diabetic cases with controls as well l as a GWAS on idiopathic versus with diabetic cases. We  
67 have delineated the expected loci in the diabetic gastroparesis cohort and furthermore, we report  
68 novel associations with the idiopathic gastroparesis.

69

70

71

72

73

74

75

76

77

78

79

80

81

82

83

84

## 85 Results

86

87 Whole-genome sequencing was done on 1385 samples obtained from consented gastroparesis  
88 patients. Samples were obtained from patients participating in two gastroparesis studies phase II  
89 clinical study (VP-VLY-686-2301 and ongoing phase III gastroparesis clinical study (VP-VLY-  
90 686-3301). Inclusion criteria included patients with idiopathic or diabetic gastroparesis with  
91 moderate to severe nausea, delayed gastric emptying, daily 50% worst average nausea score  $\geq 3$   
92 and GCSI nausea score  $\geq 3$  at screening. In the phase III study subjects included male and female  
93 adults ages 18-70 with a diagnosis of diabetic or idiopathic gastroparesis. Subjects enrolled in the  
94 study had evidence of delayed gastric emptying, and moderate to severe nausea, daily average  
95 nausea score of  $> 2.5$ , at least one episode of vomiting, PEGI-SYM nausea score of  $\geq 2$  at  
96 screening, and controlled blood glucose levels with HbA1c  $< 10\%$ . Demographics and clinical  
97 characteristics are provided in **Table 1**. Self-reported ancestry was further confirmed with  
98 Principal Component Analysis (PCA) - details provided in the Methods section. Association  
99 results were obtained from logistic models for the 4 following GWAS analyses: idiopathic vs.  
100 controls, diabetic vs. controls, gastroparesis cases vs. non gastroparesis matched controls and  
101 diabetic vs. idiopathic cases.

### 102 Idiopathic Gastroparesis

103 To avoid spurious signals resulting from population substructure, the largest set of EUR ancestry  
104 was used for the purpose of the idiopathic and diabetic analyses. The analysis consisted of  
105 variants with Minor Allele Frequency (MAF)  $> 1\%$ , EUR individuals (PCA-defined) in both cases  
106 ( $n=319$ ) and controls ( $n=896$ ). For comparisons of variant frequencies, we used both  
107 gastroparesis cohorts, controls and gnomAD<sup>8</sup> (matched by ancestry as defined by PCA). Cases  
108 and controls were called by uniform GATK pipeline, with only variants passing GATK's Variant  
109 Quality Score Recalibration – (VQSR) and internal MAF cutoffs were analyzed. Amongst the  
110 top strongest loci is a signal from variant within the Solute carrier family 15 (SLC15A4) gene -  
111 lead variant rs10847696 ( $p$ -value $<0.000004$  (OR:1.9). The non-synonymous variant of interest,  
112 NM145648:exon2:c.T716C:p.V239A, rs33990080 is also depicted on the Manhattan plot **Figure**  
113 **1A** and the SLC15A4 regional zoom plot **Figure 2**. We report 69 carriers among 214 idiopathic  
114 patients versus 165 out of 896 ancestry-matched controls (MAF: cases 0.18; MAF: controls 0.09)  
115 and OR: 1.9. The MAF of the top coding variant among all gastroparesis patients, combining  
116 both diabetic and idiopathic patients is 0.16. The global MAF among non-finnish-europeans  
117 (NFE) in a public database (gnomAD<sup>8</sup>) is 0.09. The significant effect persists when idiopathic  
118 cases are compared with diabetic cases as the MAF of diabetic cases (0.10) is comparable to that  
119 of population controls (0.09). The variant is a highly statistically significant ( $p$ -value $< 10^{-17}$ )  
120 eQTL for chr12 *GLT1D1* and *SLC15A4* (GTEx<sup>9</sup>) **Supplementary Figure 1A**. The identified  
121 variant carriers have a significantly higher nausea score at baseline with a mean difference  $\sim 0.3$   
122 unit, and  $\sim 0.6$  unit if comparing homozygotes ( $p$ -value $<0.04$ ) as shown on **Supplementary**  
123 **Figure 1B**. There are additional significant variants reported within *SLC15A4* gene in  
124 association with idiopathic gastroparesis further supporting the effect carried by identified  
125 region. The top results for the idiopathic vs. controls analysis are presented in **Table 2** as well as  
126 in the **Supplementary Material Data**. Other identified loci include intergenic variants in the  
127 region of *MIR8054* and *LUZP2* genes as well as other loci depicted in Table 2. Importantly, we

128 have furthermore replicated the effect of this *SLC15A4* variant in another batch of EUR  
129 gastroparesis samples with OR 1.6  $p$ -value $<10^5$ .

130

## 131 Diabetic vs. Idiopathic Gastroparesis

132 Whereas the primary focus of this analysis was on idiopathic rather than diabetic gastroparesis,  
133 both sets of analysis yielded informative results. In this set idiopathic controls are super controls  
134 as this is a set with a confirmed negative diabetes diagnosis. Top variants in diabetic  
135 gastroparesis GWAS included variants pointing to *HLA-DQB1* with lead variant rs9275638.  
136 Among the reported top variants is rs9273363 - a known risk factor for Type 1 diabetes, with an  
137 OR of 2.1,  $p$ -value $<10^{5}$ , a common variant with a MAF of 0.39 in diabetic gastroparesis cases  
138 versus MAF of 0.22 in idiopathic controls as well as MAF 0.27 in matched EUR controls. The  
139 variant is tagging the HLA DQB1\*03:02 haplotype and the 6q22.33 region, which contains the  
140 genes encoding protein tyrosine phosphatase receptor k (*PTPRK*). Amongst the other top  
141 variants are loci within *EXOC6B* depicted in **Figure 1B** and **Table 3**. *EXOC6B*'s top variant is a  
142 UTR variant rs41416 highly increased among diabetic but not idiopathic cases (OR 3.3,  $p$ -  
143 value $<10^{7}$ ). This exocyst complex gene has been previously associated with increased risk of  
144 Type II diabetes. We have furthermore calculated a T2D polygenetic risk score to see how well  
145 we can cluster cases. Polygenic scores were constructed for diabetes by summing the number of  
146 risk alleles carried by each individual, weighted by the effect size estimates from well-  
147 established genome-wide significant associations derived from Li et al., 2021 (60 SNPs)<sup>10</sup>. We  
148 differentiate idiopathic from diabetic gastroparesis with a diabetes genetic risk score, -  
149 statistically significant result ( $p$ -value $<0.0004$ ). This reinforces the capacity to subgroup cases  
150 based on diabetes risk score. This is presented in the **Supplementary Material Figure 2**  
151 Additionally, we explored the frequencies of previously reported variants in a functional  
152 dyspepsia GWAS<sup>11</sup>. Two variants previously reported came out as nominally significant:  
153 rs2595968 (NFASC  $p$ -value $<0.004$ ) and rs17597505 ( $p$ -value $<0.03$ ).

154

155

## 156 Discussion

157

158 Whole-genome sequencing can provide unique insights into genetic determinants of  
159 gastroparesis, by uncovering associations between common as well as rare genetic variants. Such  
160 loci can be extremely helpful, because they are often coding, thereby pointing directly to a causal  
161 gene. In this study focused primarily on idiopathic and diabetic gastroparesis cases. We report  
162 novel variants associated with idiopathic gastroparesis as well as known risk factors previously  
163 associated with diabetes. Importantly, we report a novel genetic association of the *SLC15A4*  
164 (p.Val239Ala) risk variant conferring a greater risk of idiopathic gastroparesis.

165 Solute carrier family 15 (SLC15) A4 is a lysosome-resident, amino acid/oligopeptide transporter  
166 that is preferentially expressed in immune cells<sup>12</sup>. This proton-coupled amino-acid transporter  
167 mediates the transmembrane transport of L-histidine and some di- and tripeptides from inside the  
168 lysosome to the cytosol, and plays a key role in innate immune responses. Importantly, it is  
169 required for TLR7/9-dependent type I interferon production<sup>13</sup>. SLC15A4 has been associated  
170 with disorders such as inflammatory bowel diseases and systemic lupus erythematosus<sup>13, 14</sup>. High  
171 levels of *SLC15A4* transcripts were observed in human antigen-presenting cells, including  
172 dendritic cells, activated macrophages, and B cells<sup>13</sup>. SLC15A4 was shown to mediate M1-prone  
173 metabolic shifts in macrophages and guards immune cells from metabolic stress<sup>12</sup>. SLC15A4  
174 loss disturbed the coupling of glycolysis and the TCA cycle, and SLC15A4-deficient  
175 macrophages preferred to use glutamine rather than glucose as a carbon source for the TCA  
176 cycle<sup>12</sup>. SLC15A4-deficient macrophages produced low levels of itaconate and proinflammatory  
177 IL-12 cytokine members. Correspondingly, *SLC15A4*<sup>-/-</sup> mice developed a less severe form of  
178 Th1-dependent colitis than *SLC15A4*<sup>+/+</sup> mice<sup>13</sup>. SLC15A4 was shown to promote colitis through  
179 Toll-like receptor 9 and NOD1-dependent innate immune responses. It is involved in  
180 maintaining the histidine homeostasis within intracellular compartments and is crucial for  
181 eliciting effective innate immune responses. SLC15A4-intact but not SLC15A4-deficient  
182 macrophages became resistant to fluctuations in environmental nutrient levels by limiting the use  
183 of the glutamine source; thus, SLC15A4 was critical for macrophage's respiratory homeostasis<sup>12</sup>.

184 Previous reports have shown that when the anti-inflammatory M2 macrophages are switched to  
185 pro-inflammatory M1 macrophages, delayed GE was evident in animal models<sup>4</sup>. This is  
186 consistent with the GWAS picture that is emerging where the machinery of M1 to M2  
187 macrophage polarization seems to be implicated. These findings suggest a mechanism of  
188 metabolic regulation in which an amino acid transporter acts as a gatekeeper that protects  
189 immune cells' ability to acquire an M1-prone metabolic phenotype in inflammatory tissues by  
190 mitigating metabolic stress. It seems the detected loci could be directly connected to macrophage  
191 polarization either via gain of function of hyperexpression, mechanisms that still need to be  
192 confirmed. Past reports on idiopathic cases suggested a reduction in both myenteric and  
193 intramuscular interstitial cells of Cajal at the center of the etiology of gastroparesis<sup>15</sup>. Successful  
194 gastric emptying results from the successful cooperation between smooth muscle, enteric and  
195 autonomic nerves, and ICC<sup>15</sup>. It may be the case that multiple paths lead to the same aberrant  
196 pathway such as in the M1/M2 macrophage polarization leading to gastroparesis, both of the  
197 diabetic or idiopathic etiology. In this report, we show such potential risk factors from a genetic  
198 perspective. We suggest that macrophage polarization fate could lead to the destruction of the  
199 interstitial cells of Cajal effectively leads to abnormal gastric emptying.

200 Nevertheless, our findings despite initial replication require further confirmation as the number  
201 of sequenced cases increases. Large association studies require careful control for population  
202 stratification and hence analysis was focused on EUR samples. Further analyses are necessary  
203 across other ancestries. There are other variants delineated in this study that call for further  
204 confirmation and research into their mechanisms of action. By depleting the diabetic cases and  
205 doing a sub-analysis we created a homogenous set for exploratory GWAS. We successfully  
206 detected risk for HLA-DQB1 – in the diabetes cohort - we also identified other loci that call for

207 further confirmatory studies such as EXOC6B. Despite this being the largest WGS study  
208 reported, size is still a limitation and further replication of these findings will be necessary.

209 In summary, we detected novel loci associated with idiopathic gastroparesis. We also  
210 reproduced a genome-wide significant signal for diabetic gastroparesis – a whole-genome-wide  
211 significant association between HLA-DQB1 and Type 1 diabetic gastroparesis amongst other  
212 variants. Our results also suggest an association between macrophage polarization at the center  
213 of the etiology of idiopathic gastroparesis, a mechanism that has also been implicated in the  
214 etiology of gastroparesis in patients with diabetes. Future genome-wide studies of rare variants  
215 will require a larger sample size to fully understand the genetic architecture of gastroparesis.,

216

217

218

219

220

221

222

223

224

225

226

227

228

229

## 230 **Methods:**

### 231 **Datasets**

232 Samples were obtained from patients participating in two respective gastroparesis clinical trials  
233 phase II clinical study – VP-VLY-686-2301<sup>16</sup> and phase III clinical study VP-VLY-686-3301.  
234 Inclusion criteria for both studies included patients with idiopathic or diabetic gastroparesis with  
235 moderate to severe nausea and delayed gastric emptying, as well as controlled diabetes status.  
236 The first gastroparesis dataset (phase II clinical study – VP-VLY-686-2301) was a multiethnic  
237 cohort (n = 119)<sup>16</sup>. This cohort was composed of 90.7% females; the average age was 45.9; 86.2%  
238 of the patients self-identified as White, 10.5% self-reported as Black or African American, 2%  
239 self-reported American Indian or Alaska Native and 1.3% reported as Asian. The second study  
240 (VP-VLY-686-3301) was a multiethnic cohort composed of 70.2% females; the average age was

241 48.5; 64.5% of the patients self-identified as White, 31.7% self-reported as Black or African  
242 American, 0.8% self-reported American Indian or Alaska Native and 1.9% reported as Asian.

243

## 244 Genetic analysis

245 DNA samples were quantified using fluorescent-based assays (PicoGreen) to accurately  
246 determine whether sufficient material is available for library preparation and sequencing. DNA  
247 sample size distributions were profiled by a Fragment Analyzer (Advanced Analytics) or  
248 BioAnalyzer (Agilent Technologies), to assess sample quality and integrity. WGS libraries were  
249 prepared using the Truseq DNA PCR-free Library Preparation Kit. Whole Genome data were  
250 processed on NYGC automated pipeline. Paired-end 150 bp reads were aligned to the GRCh37  
251 human reference (BWA-MEM v0.7.8) and processed with GATK best-practices workflow  
252 (GATK v3.4.0). The mean coverage was 35.8 reflecting the average of the samples. All high-  
253 quality variants obtained from GATK pipeline were functionally annotated (intronic, intergenic,  
254 splicing, nonsynonymous, stopgain and frameshifts) based on RefSeq transcripts. Cases and  
255 controls were called with the sample pipeline, only variants passing GATK's Variant Quality  
256 Score Recalibration - VQSR) internal MAF cutoff were included in the analysis.

257

258

259

260

## 261 GWAS

262 We performed a GWAS using variants with minor allele frequencies higher than 1% and allele  
263 count of 10 or more, with the same analysis design used in the landmark COVID-19 HGI  
264 GWAS<sup>17</sup>. We performed single variant association tests using a GWAS additive model  
265 framework. Logistic models adjusted for PC, age and sex were conducted in PLINK<sup>18</sup>. The  
266 analysis was limited to individuals of European (EUR) genetic ancestry due to the largest cohort  
267 available in this ancestry and in order to avoid confounders in the form of population  
268 substructure. The Principal Component Analysis and PC definitions are based on the one  
269 provided by the COVID-19 Host Genetics Initiative, available here for  
270 reference: [https://github.com/covid19-hg/pca\\_projection](https://github.com/covid19-hg/pca_projection). A common set of SNPs was used for  
271 ancestry definitions to match those for 1000 genomes project (V3).

272

273

## 274 References

275

- 276 1. Camilleri M, Chedid V, Ford AC, et al. Gastroparesis. *Nature reviews Disease primers*.  
277 2018;4(1):41. doi:10.1038/s41572-018-0038-z
- 278 2. Ye Y, Yin Y, Huh SY, Almansa C, Bennett D, Camilleri M. Epidemiology, Etiology, and

- 279 Treatment of Gastroparesis: Real-World Evidence From a Large US National Claims  
280 Database. *Gastroenterology*. 2022;162(1):109-121.e5. doi:10.1053/j.gastro.2021.09.064
- 281 3. Grover M, Farrugia G, Stanghellini V. Gastroparesis: a turning point in understanding and  
282 treatment. *Gut*. 2019;68(12):2238-2250. doi:10.1136/gutjnl-2019-318712
- 283 4. Grover M, Bernard CE, Pasricha PJ, et al. Diabetic and idiopathic gastroparesis is  
284 associated with loss of CD206-positive macrophages in the gastric antrum.  
285 *Neurogastroenterology and motility*: the official journal of the European  
286 *Gastrointestinal Motility Society*. 2017;29(6). doi:10.1111/nmo.13018
- 287 5. Neshatian L, Gibbons SJ, Farrugia G. Macrophages in diabetic gastroparesis--the missing  
288 link? *Neurogastroenterology and motility*: the official journal of the European  
289 *Gastrointestinal Motility Society*. 2015;27(1):7-18. doi:10.1111/nmo.12418
- 290 6. Atieh J, Sack J, Thomas R, Rahma OE, Camilleri M, Grover S. Gastroparesis Following  
291 Immune Checkpoint Inhibitor Therapy: A Case Series. *Digestive diseases and sciences*.  
292 2021;66(6):1974-1980. doi:10.1007/s10620-020-06440-x
- 293 7. Gibbons SJ, Grover M, Choi KM, et al. Repeat polymorphisms in the Homo sapiens heme  
294 oxygenase-1 gene in diabetic and idiopathic gastroparesis. *PloS one*.  
295 2017;12(11):e0187772. doi:10.1371/journal.pone.0187772
- 296 8. Karczewski KJ, Francioli LC, Tiao G, et al. Variation across 141,456 human exomes and  
297 genomes reveals the spectrum of loss-of-function intolerance across human protein-coding  
298 genes. *bioRxiv*. August 2019:531210. doi:10.1101/531210
- 299 9. Lonsdale J, Thomas J, Salvatore M, et al. The Genotype-Tissue Expression (GTEx)  
300 project. *Nature Genetics*. 2013;45(6):580-585. doi:10.1038/ng.2653
- 301 10. Li JH, Szczerbinski L, Dawed AY, et al. A Polygenic Score for Type 2 Diabetes Risk Is  
302 Associated With Both the Acute and Sustained Response to Sulfonylureas. *Diabetes*.  
303 2021;70(1):293-300. doi:10.2337/db20-0530
- 304 11. Garcia-Etxebarria K, Carbone F, Teder-Laving M, et al. A survey of functional dyspepsia  
305 in 361,360 individuals: Phenotypic and genetic cross-disease analyses.  
306 *Neurogastroenterology and motility*: the official journal of the European  
307 *Gastrointestinal Motility Society*. 2022;34(6):e14236. doi:10.1111/nmo.14236
- 308 12. Kobayashi T, Nguyen-Tien D, Sorimachi Y, et al. SLC15A4 mediates M1-prone  
309 metabolic shifts in macrophages and guards immune cells from metabolic stress.  
310 *Proceedings of the National Academy of Sciences*. 2021;118(33):e2100295118.  
311 doi:10.1073/pnas.2100295118
- 312 13. Sasawatari S, Okamura T, Kasumi E, et al. The solute carrier family 15A4 regulates TLR9  
313 and NOD1 functions in the innate immune system and promotes colitis in mice.  
314 *Gastroenterology*. 2011;140(5):1513-1525. doi:10.1053/j.gastro.2011.01.041
- 315 14. Katewa A, Suto E, Hui J, et al. The peptide symporter SLC15a4 is essential for the  
316 development of systemic lupus erythematosus in murine models. *PloS one*.  
317 2021;16(1):e0244439. doi:10.1371/journal.pone.0244439

- 318 15. Zárate N, Mearin F, Wang X-Y, Hewlett B, Huizinga JD, Malagelada J-R. Severe  
319 idiopathic gastroparesis due to neuronal and interstitial cells of Cajal degeneration:  
320 pathological findings and management. *Gut*. 2003;52(7):966-970.  
321 doi:10.1136/gut.52.7.966
- 322 16. Carlin JL, Lieberman VR, Dahal A, et al. Efficacy and Safety of Tradipitant in Patients  
323 With Diabetic and Idiopathic Gastroparesis in a Randomized, Placebo-Controlled Trial.  
324 *Gastroenterology*. 2021;160(1):76-87.e4. doi:10.1053/j.gastro.2020.07.029
- 325 17. Initiative C-19 HG. Mapping the human genetic architecture of COVID-19. *Nature*. 2021.  
326 doi:10.1038/s41586-021-03767-x
- 327 18. Purcell S, Neale B, Todd-Brown K, et al. PLINK: A Tool Set for Whole-Genome  
328 Association and Population-Based Linkage Analyses. *The American Journal of Human*  
329 *Genetics*. 2007;81(3):559-575. doi:10.1086/519795

330

331

332

333

334

335

336

337

338

339

340

341

342

343

344

345

346

347 Table 1. Demographics and clinical characteristics of the screened cohort of gastroparesis  
348 patients

349 Table 2. Top GWAS variants for idiopathic cases versus controls

350 Table 3. Top GWAS variants for diabetic cases versus idiopathic cases

351 Figure 1. Manhattan plots showing top results for A. GWAS: idiopathic gastroparesis versus  
 352 controls B. GWAS: diabetic gastroparesis cases versus controls

353 Figure 2. Zoom plot showing *SLC15A4* rs33990080 variant of region detected in the idiopathic  
 354 gastroparesis cases versus matched controls analysis

355  
 356  
 357  
 358  
 359  
 360

chr	bp	Ref	Alt	Type	Nearest Gene	AAChange	dbSNP	OR.idio.vs.cont	P.idio.vs.cont	MAF.diab	MAF.idio	MAF.gastro.all	MAF.nongastro	gnomAD_genome_ALL	gnomAD_genome_NFE
2	70575204	A	C	intergenic	FAM136A,TGFA	.	rs10203624	0.51	5.08E-06	0.200	0.154	0.169	0.260	0.318	0.265
2	150783253	G	A	intergenic	LINC01931,LINC01817	.	rs11689526	0.57	6.00E-06	0.400	0.271	0.314	0.385	0.316	0.377
4	168501627	G	T	intergenic	SPOCK3,ANXA10	.	rs1904115	1.67	9.16E-06	0.171	0.341	0.285	0.230	0.229	0.239
8	40159237	T	C	intergenic	C8orf4,ZMAT4	.	rs16889111	2.58	8.28E-06	0.033	0.093	0.074	0.040	0.053	0.047
9	1320866	A	G	intergenic	DMRT2,SMARCA2	.	rs72687269	4.23	8.37E-06	0.010	0.047	0.034	0.013	0.010	0.016
11	24192805	C	G	intergenic	MIR8054,LUZP2	.	rs2403906	1.89	1.14E-06	0.186	0.269	0.241	0.166	0.210	0.211
12	129297153	G	A	intronic	SLC15A4	.	rs10847696	1.99	4.13E-06	0.114	0.189	0.165	0.101	0.092	0.092
12	129299446	A	G	exonic	SLC15A4	NM_145648:exon2:c.T716C;p.V239A	rs33990080	2.01	4.81E-06	0.100	0.182	0.155	0.096	0.065	0.089
18	57217671	C	T	intronic	CCBE1	.	rs7227690	3.43	7.60E-06	0.024	0.061	0.049	0.021	0.037	0.022
19	31224845	C	T	intergenic	ZNF536,LINC01791	.	rs142557503	6.28	7.92E-06	0.029	0.035	0.033	0.006	0.009	0.015

361  
 362 Table 2

363


chr	bp	Ref	Alt	Type	Nearest Gene	ExonicFunc	dbSNP	OR.logit.diab.vs.idio	P.logit.diab.vs.idio	MAF.diab	MAF.idio	MAF.gastro.all	MAF.nongastro	gnomAD_genome_ALL	gnomAD_genome_NFE
2	72416952	TCTC	-	intronic	EXOC6B	.	rs139115191	3.36	1.45E-07	0.291	0.122	0.177	0.184	0.115	0.164
2	114998082	G	C	intergenic	LINC01191,DPP10	.	rs3132039	3.34	6.09E-06	0.229	0.096	0.140	0.120	0.090	0.129
6	32698988	A	C	intergenic	HLA-DQB1,HLA-DQA2	.	rs7751856	3.03	1.26E-07	0.610	0.435	0.492	0.462	0.489	0.540
6	32729642	C	G	exonic	HLA-DQB2	synonymous SNV	rs762815	2.5	3.45E-06	0.55	0.4	0.45	0.41	0.66	0.57
11	95405933	C	T	intergenic	LOC100129203,FAM76B	.	rs7931781	2.40	3.08E-06	0.595	0.409	0.470	0.479	0.561	0.538
12	2964735	G	A	ncRNA_intronic	LOC100507424	.	rs7138715	2.86	3.55E-06	0.286	0.143	0.190	0.191	0.263	0.176
15	78567853	G	T	exonic	DNAJA4	synonymous SNV	rs967821	2.79	1.15E-05	0.286	0.150	0.194	0.175	0.212	0.193

364  
 365 Table 3

366

367

368  
369  
370



371  
372  
373  
374  
375  
376

